Control of myogenic differentiation by fibroblast growth factor is mediated by position in the G1 phase of the cell cycle by unknown
Control of Myogenic Differentiation  by 
Fibroblast Growth Factor is Mediated by 
Position in the G1 Phase of the Cell Cycle 
BRIAN  LATHROP,* K.  THOMAS,* and L.  GLASER* 
* Department of Biological Chemistry, Division of Biology and Biomedical Sciences, Washington 
University School of Medicine, St. Louis, Missouri 63110; and *Merck, Sharp 8, Dohme Research 
Laboratories, Rahway, New Jersey 07065 
ABSTRACT  We have used the expression of the muscle form of creatine  phosphokinase (M- 
CPK) to  assay myogenic  differentiation  in  the  cloned  muscle cell  line  BC3HI. BC3HI cells 
express M-CPK when arrested in the Go portion of the cell cycle. Addition of the anionic form 
of brain fibroblast  growth factor (B-FGF) rapidly represses synthesis of M-CPK with a half-time 
of 7 h. Even though  B-FGF is not  mitogenic  for the cells, it causes quiescent  BC3HI cells to 
exit from the Go portion of the cell cycle, and to accumulate at a new restriction  point ~4 to 
6  h  in  the  G1  portion  of  the  cell  cycle.  The  repression of  M-CPK  synthesis by  B-FGF is 
reversible  upon  removal  of  B-FGF, and  cells which  have re-initiated  expression of  M-CPK 
have also returned to the Go portion of the cell cycle. The primary control of M-CPK expression 
by B-FGF appears to be at the level of gene transcription.  We conclude  that arrest of cells at 
Go but not at other positions in the Gt phase of the cell cycle provides permissive conditions 
for the expression of muscle-specific  proteins, and that defined  polypeptide growth factors, 
in this case B-FGF, are important in the control of the expression of muscle-specific proteins. 
The process of  muscle differentiation requires the coordinated 
expression (induction) of a group of proteins associated with 
the muscle phenotype (1-3). The induction of muscle-specific 
proteins occurs after myoblasts cease proliferation, and are 
arrested early in the G~ portion of the cell cycle (4, 5). 
A number of permanent cell lines can be induced to express 
proteins associated with the muscle phenotype (for review see 
reference l). Some of these cell lines,  which do not fuse to 
form multinucleated myotubes, also do not become irrevers- 
ibly committed to the differentiated phenotype. Upon addi- 
tion of mitogens, usually serum, these cells reinitiate growth 
and concomitantly the expression of muscle-specific proteins 
is repressed (5-7). We have used BC3H1 cells, a clonal muscle 
cell line, to examine the  control of cell  differentiation by 
mitogenic polypeptides using  the  muscle  form  of creatine 
phosphokinase (M-CPK) ~  as a probe to assay cell differentia- 
tion. We have reported recently that addition to differentiated 
BC3H1 cells of serum, commercial (impure) pituitary fibro- 
Abbreviations  used in this paper:  B-CPK  and M-CPK, the brain 
and muscle forms of creatine phosphokinase; B-FGF, the anionic 
form of brain fibroblast  growth factor. 
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blast growth factor, or pure anionic brain fibroblast growth 
factor (B-FGF) results in repression of M-CPK synthesis (7, 
8). Under the conditions used, B-FGF is nonmitogenic for 
BC3HI cells,  suggesting  that  it is possible  to dissociate the 
mitogenic response from  the  repression  of muscle-specific 
protein synthesis.  Observations have recently been reported 
in preliminary form showing that cell growth is not required 
for repression of muscle-specific functions (9). 
In this communication we examine in detail the repression 
of  M-CPK by addition of B-FGF to differentiated BCaHI cells. 
We demonstrate that B-FGF causes quiescent BC3H1 cells to 
exit from Go into Gl and become arrested at a new restriction 
point within Gt. The repression of M-CPK synthesis appears 
to be concomitant with, or follow shortly after, the exit of 
BC3HI cells from Go, and apparently reflects a rapid decline 
in the rate of transcription of the M-CPK gene. 
MATERIALS AND  METHODS 
Cell  Culture:  BC3HI  cells (10)  were grown in  Dulbecco's modified 
Eagle's medium supplemented with 20% fetal calf serum in an atmosphere of 
10% CO2 as described (8). Cell growth was arrested at subconfluent densities 
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indicated,  B-FGF (5 ng/ml) was added to quiescent differentiated BC3HI cells 
in a simplified medium of DME and F l2 at a 3:1 ratio supplemented with 250 
#g/ml bovine serum albumin (BSA), 50 ~g/ml transferrin,  0.25% serum, and 
antibiotics as described (8). 
Determination  of Rate of CPK Synthesis:  The rate of CPK 
synthesis was determined by immunoprecipitation  of  Triton X- 100-solubilized 
extracts that had been pulse labeled for 2 h with  100 #Ci/ml [35S]mcthionine 
as described (8). M- and B-isozymes of CPK were separated by SDS PAGE, 
and the radioactive bands were visualized by fluorography. The relative rate of 
synthesis of M-CPK was determined  by densitometry of fluorographs (8). 
Ornithine  Decarboxylase Assay:  Ornithine  decarboxylase  was 
assayed  by the release  of radioactive  CO2  from  L-ornithine  essentially  by the 
method  of Heller et al.  (I l).  Cell monolayers  were washed twice with cold 
phosphate-buffered  saline and harvested by scraping in l0 mM Tris-HC1, pH 
7.2,  50  mM  KCI, 0.1  mM  EDTA,  0.05 mM  pyridoxal  phosphate,  5 mM 
dithiothreitol,  and 0.025%  Tween  20 at 4°C. Reactions  were carried  out in 
stoppered  12-ml glass conical centrifuge tubes at 37*(? for 1 h. 150 ~1 of extract 
were added to 15 ul L-l-[~4C]ornithine  (Amersham Corp., Arlington Heights, 
IL) (8 x  10  -s M) at a final specific  radioactivity of 7.5 Ci/mol, and 10 ul of 0.5 
M Tris-HC1, pH 7.2. Reactions were quenched by injecting 0.2 ml of 10% 
trichtoroacetic acid through the stopper, and  liberated radioactive CO2 was 
trapped with a wick soaked with 100 ul of 10% NaOH held in place by a center 
well (Kontes Co., Vineland, N  J). Wells with wicks were counted in 10 ml 3a70 
scintillation fluid (Research Products International Corp., Mt. Prospect, IL). 
The assay was linear with respect to extract concentration and time. 
Other  Procedures:  Fixing,  mounting  and  developing cultures for 
autoradiography after labeling with [aH]thymidine was carried out essentially 
by the method of Cassel et al. (12). Cultures were grown on 35-mm dishes, and 
after labeling with [3H]thymidine, the cultures were washed once with 2 ml of 
phosphate-buffered saline, and fixed overnight with 2 ml of 4% paraformalde- 
hyde in the same buffer. The rim of the dishes was removed and the bottom 
processed for autoradiography (12). I uCi/ml of [3H]methylthymidine  (6.7 Ci/ 
mmol; New England Nuclear, Boston, MA) was used for 48-h labeling  of  BC3HI 
cultures. For 15-h cumulative labeling experiments, 3 uCi/ml were used. 
The rate of thymidine incorporation was measured by trichloroacetic acid- 
precipitable radioactivity incorporated after a l-h pulse with 3 uCi/ml of [3H] 
thymidine (6.7 Ci/mmol),  as described by Whittenberger and  Glaser (13). 
Uridine incorporation was measured by the same procedure after cultures had 
been pulsed with 2 ~Ci/ml of [~H]uridine (30 Ci/mmol; New England Nuclear) 
for  1 h. Labeling was linear with respect to time at these concentrations of 
isotopes. Epidermal growth factor was prepared as described (14). 
RESULTS 
When  BC3HI  cells are  cultured  in  1%  serum,  they cease to 
proliferate and synthesize muscle-specific proteins such as M- 
CPK.  Fig.  1 shows that  addition  of B-FGF to differentiated 
cells, as described in Materials and Methods, results in a rapid 
decline  of  the  rate  of  M-CPK  synthesis  as  measured  by 
immunoprecipitation from cells labeled with [3SS]methionine 
for 2 h. A half-life of 7 h  for the decline in the rate of M-CPK 
synthesis can be estimated from the data in Fig.  l, and within 
the resolution of the method the decline is initiated without 
a  significant time lag. 
The  decline  in  the  rate  of M-CPK  synthesis  observed  in 
Fig. 1 could either reflect a decrease in the rate of transcription 
of the  M-CPK  gene  or  a  specific destabilization  of the  M- 
CPK  mRNA.  A  preliminary  assessment  of which  of these 
alternatives applies can be obtained by the use ofactinomycin 
D  to block transcription in the absence of B-FGF. If the rate 
of M-CPK mRNA  degradation  is unaffected by the addition 
of B-FGF, then the decline in the rate of M-CPK should  be 
the same whether B-FGF or actinomycin D  is added to cells. 
The  data  in  Fig.  2  document  the  decline  in the  rate  of M- 
CPK  synthesis  after  addition  of actinomycin  D,  and  these 
data have been incorporated in Fig. l B (triangles). The decline 
in  the rate  of M-CPK synthesis is the same whether  B-FGF 
or actinomycin  D  are added  to cells. The observations were 
similar using different levels of actinomycin D  from 0.05  to 
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FIGURE  I  Repression of M-CPK synthesis by B-FGF. Differentiated 
BC3HI cells  were re-fed  with  medium that contained B-FGF. At 
times indicated, the cultures were pulsed for 2 h with [3SS]methio- 
nine and CPK was immunoprecipitated and the B and M  forms 
separated  by  PAGE, as  described  in  Materials  and  Methods. A 
illustrates a fluorogram of a polyacrylamide gel, and B a densitom- 
etry tracing of such fluorogram. O, controls not treated with B-FGF; 
O, cultures treated with B-FGF; A, cultures treated with 0.05 ~.g/ml 
of actinomycin D; A, control cultures  (see Fig. 2). B-FGF does not 
alter the rate of total protein synthesis in these cultures,  and in 
some instances increases total rate of protein synthesis by 20% (not 
shown). The B and M isozymes of CPK in A are indicated by arrows. 
0.2  ug/ml.  The  former  level  decreased  the  rate  of uridine 
incorporation into RNA by 89% and the latter by 97%. Under 
the  same  conditions,  the  rate  of synthesis  of a  number  of 
major cellular polypeptides detected by one-dimensional gel 
electrophoresis  was  reduced  by  <25%,  indicating  that  acti- 
nomycin-D  does  not  significantly  block  protein  synthesis 
nonspecifically under these conditions.  While these observa- 
tions  will have  to  be  confirmed  by  direct  measurements  of 
the cellular level of M-CPK mRNA, they strongly suggest that 
the major effect of B-FGF is at the level of gene transcription. 
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Differentiated cultures were treated with actinomycin  D  for  the 
duration and at the concentration indicated. Cultures were washed 
to remove actinomycin D,  and the  rate  of M-CPK  synthesis  was 
determined, as described in Materials and Methods. A fluorograph 
of  extracts which  had  been  subjected  to  gel  electrophoresis is 
shown. The M and B isozymes of CPK are indicated by arrows. The 
rate of M-CPK synthesis in the presence of 0.05 #g/ml actinomycin 
D is shown in Fig. 1 by black triangles. 
BC3HI Cells in the Presence of B-FGF Transit 
from G0 to GI 
Previous observations (8)  have indicated  that,  under our 
culture conditions, B-FGF was not mitogenic for BC3HI ceils 
as determined by cell  number 48 h after addition of B-FGF 
to cells. We have, in addition, used various combinations of 
B-FGF with insulin  (1  ~g/ml), epidermal growth factor (10 
ng/ml), dexamethasone (0.5 t~g/ml), and phorbolmyristic acid 
(100 ng/ml), and failed to observe an increase in cell number 
due to B-FGF after addition to quiescent BC3HI cells. 
A  more sensitive assay to determine whether B-FGF can 
cause even a small fraction of cells to traverse the cell cycle is 
to culture cells with [3H]thymidine in the presence of B-FGF 
and determine by autoradiography the fraction of cell nuclei 
labeled with [aH]thymidine as a  measure of the  fraction of 
cells that  have entered S-phase in the cell cycle.  48  h  after 
addition  of B-FGF and  [3H]thymidine to BC3HI cells,  only 
9.8  _  .8%  of nuclei were labeled, compared to  13.4 ___  1.6% 
in  the absence of B-FGF, confirming that  B-FGF does not 
allow BC3H1 ceils to enter S-phase. 
If B-FGF does not  cause BC3H1 cells to traverse the cell 
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FIGURE  3  Effect of B-FGF on the duration of G1. B-FGF was added 
directly to differentiated cultures at 5 ng/ml. Control cultures re- 
ceived no  B-FGF. After  incubation for the times indicated, cells 
were stimulated to enter S-phase by re-feeding with serum. The 
entry into S-phase was determined by the increased  rate of incor- 
poration of [3H]thymidine into a trichloroacetic acid-precipitable 
form. A, control cultures; II, no pretreatment;  O, 4-h pretreatment; 
O, 12-h pretreatment. 
cycle, does it nevertheless move cells from Go to G:? When 
quiescent BC3H1 cells are stimulated with serum, they enter 
S-phase after ~12 h (Fig.  3). If B-FGF causes BCsHI cells to 
move into  G,,  then  when  serum  is  added  to  BC3H1 cells 
pretreated with B-FGF, the time required  for these cells  to 
enter S-phase should be shortened. Fig. 3 illustrates that this 
is in fact observed; pretreatment of BC3H1 cells for either 4 or 
12 h with B-FGF before addition of 20% serum decreases the 
time required to enter S-phase from 12 h to 7 or 8 h, consistent 
with B-FGF permitting the movement of BCsH1 cells  ~4 h 
into Gt. Since a 4-h pretreatment with B-FGF almost maxi- 
mally reduces the duration of G: (Fig. 3), B-FGF must move 
cells rapidly  out  of Go.  The  same observations have been 
obtained in three independent experiments. The time depend- 
ence of the  movement of cells out of Go is consistent with 
time required to initiate repression of M-CPK synthesis. 
There is  a  potential  ambiguity in  measuring the  rate  of 
entry  of cells  into  S-phase  by the  use  of acid-precipitable 
thymidine which may not correlate precisely with the number 
of cells entering S-phase. We have repeated the experiment in 
Fig.  3 by measuring the number of cells entering S-phase by 
autoradiography following labeling of cells  with  [3H]thymi- 
dine  to  determine directly the  number of cells  entering  S- 
phase. The results in Fig.  4  confirm the data in  Fig.  3 and 
clearly indicate that B-FGF addition to quiescent BC3H1 cells 
brings these cells 3-4 h into GI. 
An  independent measure of entry of cells into G~  is the 
induction of ornithine decarboxylase (15).  In Fig.  5 we show 
that  addition  of B-FGF to  quiescent  BC3HI  cells  causes  a 
small but reproducible increase in  ornithine decarboxylase, 
fully consistent with the entry of these cells into G~, and arrest 
at a  new restriction point  -4-6  h  into  GI, at which  point 
induction of ornithine decarboxylase is possible. The obser- 50- 
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FIGURE  4  Autoradiography 
of  B-FGF pretreated cultures 
O  labeled  with  [3H]thymidine. 
Cells were pretreated with 12 
h with B-FGF as described in 
Fig. 3. Cells were then stimu- 
lated to enter S-phase by re- 
feeding with 20% serum in the 
presence of 1 /zCi/ml  [3H]thy- 
midine.  Cultures  were  fixed 
for  autoradiography  at  the 
_  times indicated, and the frac- 
tion of nuclei labeled with thy- 
---0'  midine  determined.  0,  no 
I  I  I  treatment; O, B-FGF pre-treat- 
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FIGURE  .5  Stimulation  of  or- 
nithine  decarboxylase  by  B- 
o  FGF.  B-FGF was  added  di- 
rectly to differentiated cells at 
5  ng/ml. Ornithine decarbox- 
ylase  was  measured  at  the 
times indicated. Cultures were 
re-fed  when  serum  was 
added.  This  control  presum- 
ably  reflects  the  maximum 
o  possible  stimulation  of  orni- 
f  thine  decarboxylase achieva- 
ble under these conditions. 0, 
O  A 
e.--"--zx~e~e  1% serum; O, 20% serum; A, 
B-FGF. 
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vation that  ornithine  decarboxylase is  activated by B-FGF 
indicates that this growth factor activates at least some of the 
ordered series of events that occur when cells are stimulated 
to transit G~ (16,  17). Because various components in serum 
may also influence the induction of ornithine decarboxylase, 
we do not believe  that the absolute level of ornithine decar- 
boxylase after the addition of B-FGF to quiescent cells can be 
compared in a meaningful way with the level observed after 
addition of serum. 
Is the Repression of M-CPK Synthesis by 
B-FGF Reversible? 
Since  B-FGF causes  BC3HI cells to arrest within O~, and 
simultaneously represses M-CPK synthesis,  is this repression 
reversible,  and is it reversible  in the absence of progression 
through the  cell  cycle?  To answer  this  question,  quiescent 
BCaH1 cells, which synthesize M-CPK, were treated with B- 
FGF for 48 h. Control cells received fresh B-FGF at 24 h. 24 
h  after addition of B-FGF, the rate  of M-CPK synthesis  is 
depressed  (Fig. 6; compare lane 2 with lane 4). However, 48 
h after addition of B-FGF (in the absence of daily addition of 
B-FGF),  the  rate  of M-CPK synthesis  has  returned  to  the 
fully-induced level (compare lanes  3 and 5), indicating that 
the  repression  is  reversible.  The  reinduction at  48  h  most 
likely reflects the depletion of B-FGF from the medium, and 
FIGURE  6  Reinduction of CPK  expression after repression  by  B- 
FGF. B-FGF was added directly to differentiated cultures at 5 ng/ 
ml at the times indicated. The rate of M-CPK synthesis was deter- 
mined with [~SS]methionine. Note that 48 h after addition of B-FGF 
the cells synthesized M-CPK  maximally. If B-FGF is added each 24 
h  (lane  6),  the  cells  remain  repressed.  B-FGF thus  has  a  short 
functional half-life in these cultures, probably <24 h. The B and M 
isozymes of CPK are indicated at left. 
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FIGURE  7  Re-induced  cells 
reside  in  Go.  Cultures  were 
S  treated  with  B-FGF  as  de- 
scribed in  Fig. 6.  After 48  h, 
serum  was  added  to  these 
cells and control cultures, and 
the duration of G1 was deter- 
mined  by  [3H]thymidine  in- 
8  corporation  as  described  in 
J  Fig. 3.  Note that under these 
e/II  conditions (compare with Fig. 
=  ~  ,  J  ,  3), there is no difference in the 
9  12  15  18  21  duration of G1 in the two cul- 
TIME (hours) 
tures. 
continued addition of B-FGF maintains the repressed  state 
(compare lane 6 with lane 5). 
We  asked  whether  the  cells  under these  conditions had 
returned to Go by measuring the time required for such cells 
to enter S-phase after stimulation by serum. The data in Fig. 
? are consistent with these  cells having returned to Go. Cells 
which have re-entered  the differentiation program after ex- 
posure to B-FGF are indistinguishable  from cells never ex- 
posed to B-FGF when we measure the time required by these 
LATHROP  ET  AL.  Myogenic Differentiation  2197 cells to enter S-phase after addition of 20%  serum (Fig.  7). 
Labeling of cells with [3H]thymidine during the 48-h reversal 
period,  followed  by  autoradiography,  indicates  that  only 
13% of the cells traversed the S-phase either in the presence 
or absence of B-FGF and, therefore, that the majority of the 
cells returned  to Go without  traversing the  cell cycle.  It is 
known from other cells that commitment to proceed through 
the cell cycle is a late event in GI (16). B-FGF-treated BC3HI 
cells are arrested early in G~, presumably before this commit- 
ment point is reached. 
DISCUSSION 
The original definition of Go was that of a restriction point 
early in Gt, at which normal cells arrested in the absence of 
mitogens (16). Several observations suggest that Go represents 
a  unique metabolic state of quiescent cells and that, during 
logarithmic  growth,  cells  bypass Go  and  never  enter  this 
metabolic state (see, for example, references 16,  18, and 19). 
Our observations define the metabolic state of BCaH1 cells 
and, by inference, of other muscle cells as the state which is 
permissive for the expression of muscle-specific proteins. 
The addition  of polypeptide growth  factors to  quiescent 
BCaH1 cells initiates movement of the cells  from Go to G~. 
Exit of the cells from Go appears to be closely associated with 
repression  of the  synthesis  of M-CPK.  Though  our  data 
suggest that B-FGF allows BC3H1 cells to progress rapidly into 
G~ (see Fig.  3), the repression of M-CPK synthesis seems to 
start immediately after addition of B-FGF so that, 3 h  after 
addition of this growth factor, the rate of M-CPK synthesis is 
already decreased by 40%. 
Although  all the  experiments reported here were carried 
out with B-FGF, we have recently carried out similar experi- 
ments with identical results with highly purified pituitary FGF 
prepared as described by Bohlen et al.  (20).  Although these 
two  polypeptide growth  factors are  distinct  proteins,  their 
metabolic effects on BC3H1 are very similar. 
Differentiation of a few other cell lines has been examined 
carefully regarding the role of different compartments in the 
cell  cycle  in  the  differentiation  process.  For  example,  the 
conversion of 3T3 preadypocytes to adypocytes occurs in Go, 
but arrest of cells later in the cell cycle is nonpermissive for 
adypocyte differentiation (21, 22). 
We would suggest that the control by polypeptide growth 
factors of cell differentiation is not only relevant to established 
cell lines in culture, but may also be of importance in con- 
trolling the expression of muscle cell proteins in vivo, first in 
preventing differentiation during periods of active cell prolif- 
eration, but also in mature cells by controlling the expression 
of gene products characteristic of differentiated cells in the 
absence of cell division. Note that in BC3HI cells it is possible 
to go from a differentiated phenotype (high rate of synthesis 
of M-CPK) to a relatively undifferentiated state (low rate of 
synthesis of M-CPK) and back again to the differentiated state 
in the absence of cell division, and to do so without traversing 
the cell cycle by simply controlling the level of B-FGF in the 
culture medium. A critical test of the validity of this specula- 
tion will require an increased understanding of the role of B- 
FGF in the whole animal. 
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